DexCom, Inc. (DXCM)
Market Cap | 45.29B |
Revenue (ttm) | 2.91B |
Net Income (ttm) | 341.20M |
Shares Out | 386.41M |
EPS (ttm) | 0.82 |
PE Ratio | 142.94 |
Forward PE | 120.48 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,319,699 |
Open | 113.95 |
Previous Close | 113.93 |
Day's Range | 113.95 - 117.43 |
52-Week Range | 66.89 - 134.77 |
Beta | 1.09 |
Analysts | Buy |
Price Target | 135.40 (+15.52%) |
Earnings Date | Apr 27, 2023 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is ... [Read more]
Financial Performance
In 2022, DexCom's revenue was $2.91 billion, an increase of 18.84% compared to the previous year's $2.45 billion. Earnings were $341.20 million, an increase of 57.31%.
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for DXCM stock is "Buy." The 12-month stock price forecast is $135.4, which is an increase of 15.52% from the latest price.
News

DexCom Comments on SVB Relationship
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC arti...

Silicon Valley Bank signed exclusive banking deals with some clients, leaving them unable to diversify
Silicon Valley Bank required some clients to agree to exclusivity clauses, disabling them from diversifying where they held their money, SEC records show.

5 Stocks That Powered Nasdaq ETF Last Week
The tech-heavy Nasdaq Composite Index outperformed last week, gaining 2.6%, while the S&P 500 and the Dow Jones were up 1.9% and 1.7%, respectively.

Dexcom Announces Upcoming Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: Sean Christensen, Vice Pres...
Dexcom drops on report that Apple has made glucose tracking breakthrough
A new breakthrough by Apple could be bad news for medical device company Dexcom. With CNBC's Melissa Lee and the Fast Money traders, Karen Finerman, Dan Nathan, Courtney Garcia and Guy Adami.
Dexcom shares fall on news Apple is progressing on glucose tracking for watch
CNBC's Steve Kovach joins the 'Halftime Report' to report on Dexcom shares dropping on news that Apple is making progress on including a glucose tracking feature on the Apple Watch.

Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally
SAN DIEGO--(BUSINESS WIRE)-- #Dexcom--Dexcom Showcases Accuracy, Simplicity and Connectivity of its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally

Dexcom G6 Continuous Glucose Monitoring System Launches in Singapore
SINGAPORE--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of its Dexcom G6 CGM Syste...

Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom G7 Continuous Glucose Monitoring System Will be Available to Medicare Beneficiaries at Launch
Dexcom CEO on working with insurance companies
Cramer spoke with Dexcom CEO Kevin Sayer on Friday.

DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong
DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates
DexCom (DXCM) delivered earnings and revenue surprises of 30.77% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #cgm--Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Dario Partners to Integrate Dexcom CGM Data
New integration will improve access to Dario's multi-chronic platform for more people living with diabetes NEW YORK , Feb. 8, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a l...

Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System
Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System

Mednow Launches New Virtual Diabetes Management Program in Partnership With Dexcom
TORONTO--(BUSINESS WIRE)--Mednow Inc. (“Mednow” or the “Company”) (TSXV: MNOW) (OTCQX: MDNWF) announced today the launch of its enhanced Virtual Diabetes Management program, an end-to-end digital di...

Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 20...

The Top 7 “Millionaire-Maker” Long-Term Stocks for 2023
Study after study shows that a long-term buy-and-hold investing strategy works best. A long-term investment is generally defined as any position in a stock that is held for a year or longer.

Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCG...

DexCom (DXCM) Announces Solid Preliminary Q4 Revenues
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth q...

Dexcom Appoints Teri Lawver as Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the ...

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised)
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P...